
Arjun Sahgal
Research Assistant:
Dr. Arjun Sahgal is an international clinical and research leader in the field of high precision stereotactic radiation to the brain and spine for both metastases and primary tumors and to oligometastases. He has published over 600 peer-reviewed papers including in high impact journals like the Journal of Clinical Oncology, Lancet Oncology and New England Journal of Medicine, and 40 international guidelines specific to SRS and SBRT. He has given over 200 lectures as an invited international speaker. He invented the 24 Gy in 2 SBRT fractions regimen for spinal metastases which was tested in his landmark international CCTG SC24 randomized trial, proving superiority over conventional palliative radiation with respect to complete pain response. He developed the field of MR Linac adaptive radiotherapy for High Grade Glioma, and built an internationally recognized imaging and therapeutic research program. His group has presented the first trial to evaluate treatment volume reduction via weekly, on-line and real time, MR adaptive radiation (UNITED). He continues his research and collaborations specific to adaptive RT, vertebral compression fracture risk prediction using machine learning methods and leads the Canadian randomized trial of SBRT vs. conventional radiation for non-spine bone metastases (CCTG SC-29).
Education
- MD, 2021, Ottawa University,
Appointments & Affiliations
- Senior Scientist, Physical Sciences, Odette Cancer Research Program
- Professor, Department of Radiation Oncology, University of Toronto
Affiliated Labs & Programs
Selected Publications
-
Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, Butler J, Chow E, Fehlings MG, Foote M, Gabos Z, Greenspoon J, Kerba M, Lee Y, Liu M, Liu SK, Thibault I, Wong RK, Hum M, Ding K, Parulekar WR; trial investigators. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2021 Jul;22(7):1023-1033. doi: 10.1016/S1470-2045(21)00196-0. Epub 2021 Jun 11. PMID: 34126044.
-
Tseng CL, Chen H, Stewart J, Lau AZ, Chan RW, Lawrence LSP, Myrehaug S, Soliman H, Detsky J, Lim-Fat MJ, Lipsman N, Das S, Heyn C, Maralani PJ, Binda S, Perry J, Keller B, Stanisz GJ, Ruschin M, Sahgal A. High grade glioma radiation therapy on a high field 1.5 Tesla MR-Linac - workflow and initial experience with daily adapt-to-position (ATP) MR guidance: A first report. Front Oncol. 2022 Nov 28;12:1060098. doi: 10.3389/fonc.2022.1060098. PMID: 36518316; PMCID: PMC9742425.
-
Jabehdar Maralani P, Myrehaug S, Mehrabian H, Chan AKM, Wintermark M, Heyn C, Conklin J, Ellingson BM, Rahimi S, Lau AZ, Tseng CL, Soliman H, Detsky J, Daghighi S, Keith J, Munoz DG, Das S, Atenafu EG, Lipsman N, Perry J, Stanisz G, Sahgal A. Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma. Radiother Oncol. 2021 Mar;156:258-265. doi: 10.1016/j.radonc.2020.12.037. Epub 2021 Jan 5. PMID: 33418005; PMCID: PMC8186561.
-
Sahgal A, Atenafu EG, Chao S, Al-Omair A, Boehling N, Balagamwala EH, Cunha M, Thibault I, Angelov L, Brown P, Suh J, Rhines LD, Fehlings MG, Chang E. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol. 2013 Sep 20;31(27):3426-31. doi: 10.1200/JCO.2013.50.1411. Epub 2013 Aug 19. PMID: 23960179; PMCID: PMC6076012.
-
Poon I, Erler D, Dagan R, Redmond KJ, Foote M, Badellino S, Biswas T, Louie AV, Lee Y, Atenafu EG, Ricardi U, Sahgal A. Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis. JAMA Netw Open. 2020 Nov 2;3(11):e2026312. doi: 10.1001/jamanetworkopen.2020.26312. PMID: 33196810; PMCID: PMC7670310.